Business Description
Founded in 2015 and based in Suwon-si, South Korea, Genome & Company is an early-stage biotechnology firm working to bring new treatments to patients with cancer, skin conditions, and neurological disorders across multiple global markets. The company's pipeline includes GEN-001, an oral therapy designed to regulate the immune system through the gut microbiome, along with GEN-501 for patients with atopic skin disease who do not respond well to existing treatments, and GENA-104 targeting solid tumors. Genome & Company also collaborates with US-based Scioto Biosciences on SB-121, a treatment aimed at Autism Spectrum Disorder and conditions linked to gut injury such as Necrotizing Enterocolitis.
